Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: billkirn who wrote (3646)	1/22/1998 11:28:00 AM
From: sam	Read Replies (1) of 6136

European approval! Finally. biz.yahoo.com Bill: AGPH seems to move in anticpation of earnings. Then it is taken down. Quarter after quarter. Fortunately, there are other positive events that will keep the stock from being hit and may move it up BEFORE the next earnings announcement. That said, I think you hit the nail on the head in one of your earlear posts. Despite its unprecedented success in developing and marketing Viracept, and despite the other (potential blockbuster?) drugs in its pipeline, AGPH is still perceived by many on the street as a one drug company. When that perception changes, I believe the share price will rise accordingly.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next